New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:01 EDTADT, SSTK, BSMX, RGLS, MUSA, KYTH, ICPT, CHTR, ANFI, AMBA, WDAYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADT Corp. (ADT) initiated with a Buy at Citigroup... Ambarella (AMBA) initiated with a Buy at Deutsche Bank... Amira Nature Foods (ANFI) initiated with a Buy at Deutsche Bank... Charter (CHTR) initiated with an Underweight at Barclays... Intercept Pharmaceuticals (ICPT) initiated with a Buy at Needham... Kythera Biopharmaceuticals (KYTH) initiated with a Neutral at Goldman... Metals USA (MUSA) initiated with an Outperform at Wells Fargo... Regulus Therapeutics (RGLS) initiated with a Buy at Needham... Santander Mexico (BSMX) initiated with a Buy at Citigroup... Shutterstock (SSTK) initiated with a Buy at Jefferies... Workday (WDAY) initiated with a Buy at Canaccord.
News For ADT;AMBA;ANFI;CHTR;ICPT;KYTH;MUSA;RGLS;BSMX;SSTK;WDAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
09:13 EDTAMBAAmbarella management to meet with Topeka
Meeting to be held in San Francisco on October 23 hosted by Topeka.
08:00 EDTCHTRHBO may have fight with cable operators over OTT service price, Reuters says
Subscribe for More Information
October 15, 2014
09:21 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
07:24 EDTICPTIntercept management to meet with Deutsche Bank
Subscribe for More Information
06:23 EDTAMBAAmbarella initiated with an Outperform at Pacific Crest
Subscribe for More Information
October 14, 2014
08:08 EDTRGLSRegulus Therapeutics to present new preclinical data on multiple programs
Regulus Therapeutics (RGLS) announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at the 10th Annual Oligonucleotide Therapeutics Society meeting being held October 12-October 15 at the Hilton San Diego Resort and Spa. In a poster titled "Anti-Diabetic Activity of miR-103/107 Anti-miRs", Regulus scientists will present preclinical data further demonstrating the potential benefit of a microRNA therapeutic for the treatment of metabolic disorders. In a poster titled "Inhibition of miR-21 with RG-012 Improves Renal Function and Survival in Multiple Strains of Col4A3 Deficient Mice", Regulus scientists, in collaboration with its strategic alliance partner Sanofi (SNY), will present new preclinical data demonstrating that weekly subcutaneous delivery of RG-012 has shown to provide both glomerular and tubule protection in the kidneys of Col4A3 deficient mice in an Alport syndrome model.
October 13, 2014
10:08 EDTWDAYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTWDAYHP could buy lower valuation company, says Bernstein
Subscribe for More Information
09:03 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
08:27 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
07:12 EDTRGLSOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
06:50 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
October 9, 2014
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
October 8, 2014
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
October 7, 2014
10:02 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTICPTIntercept initiated with an Outperform at JMP Securities
Subscribe for More Information
07:23 EDTMUSAWells Fargo to hold a forum
2014 Convenience Store Forum is being held in Las Vegas on October 7-8.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use